First Financial Bancorp announced its Q3 2026 results with adjusted earnings per diluted share of $0.84, an 11% increase from the previous year and the highest in company history. The bank saw a 4.9% annualized loan growth and a net interest margin increase to 4.07%. Noninterest income hit a record $77.6 million, driven by wealth management and foreign exchange gains. The company received federal approval for its acquisition of Finward, expected to close on January 1, 2027, signaling growth and expansion opportunities ahead.
First Financial Bancorp's record third quarter results come alongside a Financials-sector market snapshot from Pluang as of Oct 28, 2026 03:12 WIB: out of 142 priced US financial stocks, 78 rose and 63 fell. Notable movers include GEMI at USD 3.07 with a 6.97% increase and 100% sell order activity, HUT at USD 67.29 up 6.86% with 96% buy order activity, and WULF at USD 12.71 rising 6.14% with 60% buy order activity. Typical hold times range from 12 to 20 days among these stocks.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
